702 related articles for article (PubMed ID: 15753456)
1. Critical update and emerging trends in epidermal growth factor receptor targeting in cancer.
Baselga J; Arteaga CL
J Clin Oncol; 2005 Apr; 23(11):2445-59. PubMed ID: 15753456
[TBL] [Abstract][Full Text] [Related]
2. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer.
Mendelsohn J; Baselga J
J Clin Oncol; 2003 Jul; 21(14):2787-99. PubMed ID: 12860957
[TBL] [Abstract][Full Text] [Related]
3. Targeting epidermal growth factor receptor signaling: early results and future trends in oncology.
Lage A; Crombet T; González G
Ann Med; 2003; 35(5):327-36. PubMed ID: 12952019
[TBL] [Abstract][Full Text] [Related]
4. Epidermal growth factor receptor targeting in cancer.
Mendelsohn J; Baselga J
Semin Oncol; 2006 Aug; 33(4):369-85. PubMed ID: 16890793
[TBL] [Abstract][Full Text] [Related]
5. Epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs): simple drugs with a complex mechanism of action?
Normanno N; Maiello MR; De Luca A
J Cell Physiol; 2003 Jan; 194(1):13-9. PubMed ID: 12447985
[TBL] [Abstract][Full Text] [Related]
6. Targeted therapies for non-small-cell lung cancer: biology, rationale, and preclinical results from a radiation oncology perspective.
Raben D; Helfrich B; Bunn PA
Int J Radiat Oncol Biol Phys; 2004; 59(2 Suppl):27-38. PubMed ID: 15142632
[TBL] [Abstract][Full Text] [Related]
7. EGFR targeting therapies: monoclonal antibodies versus tyrosine kinase inhibitors. Similarities and differences.
Dassonville O; Bozec A; Fischel JL; Milano G
Crit Rev Oncol Hematol; 2007 Apr; 62(1):53-61. PubMed ID: 17324578
[TBL] [Abstract][Full Text] [Related]
8. Rational bases for the development of EGFR inhibitors for cancer treatment.
Bianco R; Gelardi T; Damiano V; Ciardiello F; Tortora G
Int J Biochem Cell Biol; 2007; 39(7-8):1416-31. PubMed ID: 17596994
[TBL] [Abstract][Full Text] [Related]
9. Aberrant epidermal growth factor receptor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer.
Amann J; Kalyankrishna S; Massion PP; Ohm JE; Girard L; Shigematsu H; Peyton M; Juroske D; Huang Y; Stuart Salmon J; Kim YH; Pollack JR; Yanagisawa K; Gazdar A; Minna JD; Kurie JM; Carbone DP
Cancer Res; 2005 Jan; 65(1):226-35. PubMed ID: 15665299
[TBL] [Abstract][Full Text] [Related]
10. Clinical implications of EGFR expression in the development and progression of solid tumors: focus on non-small cell lung cancer.
Ettinger DS
Oncologist; 2006 Apr; 11(4):358-73. PubMed ID: 16614231
[TBL] [Abstract][Full Text] [Related]
11. EGFR signaling and drug discovery.
Lurje G; Lenz HJ
Oncology; 2009; 77(6):400-10. PubMed ID: 20130423
[TBL] [Abstract][Full Text] [Related]
12. Resistance to epidermal growth factor receptor-targeted therapy.
Morgillo F; Lee HY
Drug Resist Updat; 2005 Oct; 8(5):298-310. PubMed ID: 16172017
[TBL] [Abstract][Full Text] [Related]
13. Mutations of the epidermal growth factor receptor gene and related genes as determinants of epidermal growth factor receptor tyrosine kinase inhibitors sensitivity in lung cancer.
Mitsudomi T; Yatabe Y
Cancer Sci; 2007 Dec; 98(12):1817-24. PubMed ID: 17888036
[TBL] [Abstract][Full Text] [Related]
14. Ongoing first-line studies of epidermal growth factor receptor tyrosine kinase inhibitors in select patient populations.
Jänne PA
Semin Oncol; 2005 Dec; 32(6 Suppl 10):S9-15. PubMed ID: 16459174
[TBL] [Abstract][Full Text] [Related]
15. Antitumor activity of a dual epidermal growth factor receptor and ErbB2 kinase inhibitor MP-412 (AV-412) in mouse xenograft models.
Suzuki T; Fujii A; Ohya J; Nakamura H; Fujita F; Koike M; Fujita M
Cancer Sci; 2009 Aug; 100(8):1526-31. PubMed ID: 19459856
[TBL] [Abstract][Full Text] [Related]
16. Dual inhibition of ErbB1 (EGFR/HER1) and ErbB2 (HER2/neu).
Reid A; Vidal L; Shaw H; de Bono J
Eur J Cancer; 2007 Feb; 43(3):481-9. PubMed ID: 17208435
[TBL] [Abstract][Full Text] [Related]
17. EGFR-directed therapies to treat non-small-cell lung cancer.
Ho C; Laskin J
Expert Opin Investig Drugs; 2009 Aug; 18(8):1133-45. PubMed ID: 19572809
[TBL] [Abstract][Full Text] [Related]
18. Selecting patients for treatment with epidermal growth factor tyrosine kinase inhibitors.
Bonomi PD; Buckingham L; Coon J
Clin Cancer Res; 2007 Aug; 13(15 Pt 2):s4606-12. PubMed ID: 17671150
[TBL] [Abstract][Full Text] [Related]
19. Epidermal growth factor receptor and response of head-and-neck carcinoma to therapy.
Ang KK; Andratschke NH; Milas L
Int J Radiat Oncol Biol Phys; 2004 Mar; 58(3):959-65. PubMed ID: 14967456
[TBL] [Abstract][Full Text] [Related]
20. Regeneration of human epidermis on acellular dermis is impeded by small-molecule inhibitors of EGF receptor tyrosine kinase.
Forsberg S; Ostman A; Rollman O
Arch Dermatol Res; 2008 Oct; 300(9):505-16. PubMed ID: 18446355
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
